Clinical Trial Update: Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial in clear cell renal cell carcinoma comparing single-agent belzutifan or pembrolizumab versus their combination. The study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Belzutifan (belzutifan)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: RECRUITING